Janssen begins Phase IIb study of drug combination to treat hepatitis C virus infection

Janssen Research& Development has begun its Phase IIb study of combination of simeprevir, odalasvir and AL-335 to treat chronic hepatitis C virus infection without cirrhosis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news